Craniospinal irradiation with concurrent temozolomide and nimotuzumab in a child with primary metastatic diffuse intrinsic pontine glioma. A compassionate use treatment
Standard
Craniospinal irradiation with concurrent temozolomide and nimotuzumab in a child with primary metastatic diffuse intrinsic pontine glioma. A compassionate use treatment. / Müller, K; Schlamann, A; Seidel, C; Warmuth-Metz, M; Christiansen, H; Vordermark, D; Kortmann, R-D; Kramm, C M; von Bueren, A O.
In: STRAHLENTHER ONKOL, Vol. 189, No. 8, 01.08.2013, p. 693-6.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Craniospinal irradiation with concurrent temozolomide and nimotuzumab in a child with primary metastatic diffuse intrinsic pontine glioma. A compassionate use treatment
AU - Müller, K
AU - Schlamann, A
AU - Seidel, C
AU - Warmuth-Metz, M
AU - Christiansen, H
AU - Vordermark, D
AU - Kortmann, R-D
AU - Kramm, C M
AU - von Bueren, A O
N1 - Seidel Leipzig, von Bueren Göttingen
PY - 2013/8/1
Y1 - 2013/8/1
N2 - Primary metastatic diffuse intrinsic pontine glioma (DIPG) is relatively rare and associated with a dismal prognosis. Combining craniospinal irradiation (CSI) with concurrent temozolomide and nimotuzumab therapy may slightly improve tumor control and overall survival. However, little is known about the feasibility and toxicity of this treatment approach. Here, we describe the case of an 8-year-old girl with primary metastatic DIPG who received craniospinal radiotherapy, a local boost, and concurrent temozolomide and nimotuzumab treatment based on an individual therapy recommendation. Radiotherapy could be completed without any interruption. However, concurrent temozolomide had to be disrupted several times due to considerable acute myelotoxicity (grade III-IV).Maintenance immunochemotherapy could be started with a delay of 5 days and was performed according to treatment schedule. The disease could be stabilized for a few months. A routine MRI scan finally depicted disease progression 5.7 months after the start of irradiation. The patient died 1.9 months later.
AB - Primary metastatic diffuse intrinsic pontine glioma (DIPG) is relatively rare and associated with a dismal prognosis. Combining craniospinal irradiation (CSI) with concurrent temozolomide and nimotuzumab therapy may slightly improve tumor control and overall survival. However, little is known about the feasibility and toxicity of this treatment approach. Here, we describe the case of an 8-year-old girl with primary metastatic DIPG who received craniospinal radiotherapy, a local boost, and concurrent temozolomide and nimotuzumab treatment based on an individual therapy recommendation. Radiotherapy could be completed without any interruption. However, concurrent temozolomide had to be disrupted several times due to considerable acute myelotoxicity (grade III-IV).Maintenance immunochemotherapy could be started with a delay of 5 days and was performed according to treatment schedule. The disease could be stabilized for a few months. A routine MRI scan finally depicted disease progression 5.7 months after the start of irradiation. The patient died 1.9 months later.
KW - Antibodies, Monoclonal, Humanized
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Brain Stem Neoplasms
KW - Chemoradiotherapy
KW - Child
KW - Dacarbazine
KW - Fatal Outcome
KW - Female
KW - Glioma
KW - Humans
KW - Spinal Neoplasms
KW - Treatment Outcome
U2 - 10.1007/s00066-013-0370-x
DO - 10.1007/s00066-013-0370-x
M3 - SCORING: Journal article
C2 - 23754473
VL - 189
SP - 693
EP - 696
JO - STRAHLENTHER ONKOL
JF - STRAHLENTHER ONKOL
SN - 0179-7158
IS - 8
ER -